Physician profile
Margo H Lederhandler
NPI 1316331762
$817.75
in general payments reported to CMS, 2019-2025
11 companies · $37.18 in 2025
The $37.18 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $143 · 2021: $59.24 · 2022: $88.97 · 2023: $196 · 2024: $293 · 2025: $37.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $169.19 | 2021-2025 | Blu-U, Odomzo, Ilumya |
| Galderma Laboratories, L.P. | $150.51 | 2020-2023 | |
| Lilly USA, LLC | $106.44 | 2023-2024 | Taltz, Olumiant |
| Abbvie INC. | $91.78 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $90.91 | 2020-2024 | Libtayo, Dupixent |
| Epi Health, LLC | $62.81 | 2020-2022 | |
| Incyte Corporation | $42.50 | 2022-2025 | Opzelura |
| Pfizer INC. | $31.15 | 2020 | |
| Revance Therapeutics, INC. | $31.13 | 2024 | Daxxify |
| Novartis Pharmaceuticals Corporation | $22.76 | 2023 | |
| Arcutis Biotherapeutics, INC. | $18.57 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margo Lederhandler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.